Pharmacological approaches to methamphetamine dependence: a focused review

Karila, Laurent; Weinstein, Aviv; Aubin, Henri‐Jean; Benyamina, Aminé; Reynaud, Michel; Batki, Steven L.

doi:10.1111/j.1365-2125.2010.03639.x

Cited by 214 publications

(188 citation statements)

References 131 publications

(133 reference statements)

Supporting

Mentioning

182

Contrasting

Unclassified

Order By: Relevance

“…With continued interest in modafinil as a potential pharmacotherapy for stimulant abuse (Karila et al, 2010), our results indicate that improvements in cognitive function elicited by the medication may augment traditional behavioral therapies and increase their efficacy. Modafinil or other cognition-enhancing medications may therefore be useful adjuncts to behavioral treatments for stimulant dependence.…”

Section: Discussionmentioning

confidence: 84%

Effect of Modafinil on Learning and Task-Related Brain Activity in Methamphetamine-Dependent and Healthy Individuals

Ghahremani

Tabibnia

Monterosso

et al. 2011

Neuropsychopharmacol

109

View full text Add to dashboard Cite

Methamphetamine (MA)-dependent individuals exhibit deficits in cognition and prefrontal cortical function. Therefore, medications that improve cognition in these subjects may improve the success of therapy for their addiction, especially when cognitive behavioral therapies are used. Modafinil has been shown to improve cognitive performance in neuropsychiatric patients and healthy volunteers. We therefore conducted a randomized, double-blind, placebo-controlled, cross-over study, using functional magnetic resonance imaging, to examine the effects of modafinil on learning and neural activity related to cognitive function in abstinent, MA-dependent, and healthy control participants. Modafinil (200 mg) and placebo were administered orally (one single dose each), in counterbalanced fashion, 2 h before each of two testing sessions. Under placebo conditions, MA-dependent participants showed worse learning performance than control participants. Modafinil boosted learning in MA-dependent participants, bringing them to the same performance level as control subjects; the control group did not show changes in performance with modafinil. After controlling for performance differences, MAdependent participants showed a greater effect of modafinil on brain activation in bilateral insula/ventrolateral prefrontal cortex and anterior cingulate cortices than control participants. The findings suggest that modafinil improves learning in MA-dependent participants, possibly by enhancing neural function in regions important for learning and cognitive control. These results suggest that modafinil may be a suitable pharmacological adjunct for enhancing the efficiency of cognitive-based therapies for MA dependence. Neuropsychopharmacology (2011) 36, 950-959;

show abstract

Section: Discussionmentioning

confidence: 84%

Effect of Modafinil on Learning and Task-Related Brain Activity in Methamphetamine-Dependent and Healthy Individuals

Ghahremani

Tabibnia

Monterosso

et al. 2011

Neuropsychopharmacol

109

View full text Add to dashboard Cite

show abstract

“…Methamphetamine (METH) is one of most prevalent addictive central nervous system (CNS) stimulant drugs (Cruickshank and Dyer, 2009;Krasnova and Cadet 2009;Karila et al, 2010;Marshall and O'Dell, 2012). Recent studies have suggested that METH is a neurotoxic drug that can cause pathological changes and death in neuronal and glial cells (Thompson et al, 2004;Kitamura et al, 2007Kitamura et al, , 2010Takeichi et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Melatonin suppresses methamphetamine-triggered endoplasmic reticulum stress in C6 cells glioma cell lines

et al. 2017

View full text Add to dashboard Cite

-Methamphetamine (METH) is a neurotoxic drug that causes brain damage by inducing neuronal and glial cell death together with glial cell hyperactivity-mediated progressive neurodegeneration. Previous studies have shown that METH induced glial cell hyperactivity and death via oxidative stress, the inflammatory response, and endoplasmic reticulum stress (ER stress) mechanisms, and melatonin could reverse these effects. However, the exact mechanism of the protective role of melatonin in METH-mediated ER stress has not been understood. This study investigated the protective effect of melatonin against METH toxicity-mediated ER stress in glial cells. Our study demonstrated that METH increased glial cell toxicity related to METH-induced ER stress by stimulating the unfolded protein response (UPR) to activate the expression of ER stress transducers, including phosphorylated doublestranded RNA-activated protein kinase (PKR)-like ER kinase (p-PERK), activating transcription factor (ATF6), and phosphorylated inositol-requiring enzyme 1 (p-IRE1). Moreover, the expression of binding immunoglobulin protein (Bip), CCAAT/enhancer-binding protein homologous protein (CHOP), caspase-12, phosphorylated eukaryotic translation initiation factor 2 alpha (p-eIF2α) and spliced X-box-binding protein-1 (XBP-1) mRNA were also increased. Melatonin reduced ER stress induced by METH toxicity by reducing the expression of ER stress response genes and proteins in a concentration-dependent manner. In addition, melatonin promoted the expression of Bip chaperone in a concentration-dependent manner. Taken together, our findings suggest that melatonin can protect against ER stress-induced glial cell death induced by METH.

show abstract

“…The withdrawal syndrome will be peaked within 2-4 days and will eliminate after a week and depression associated with suicidal ideation and attempts are the most important symptoms of abstinence (5). The efficiency of pharmacological intervention for treatment of Methamphetamine related disorders is not clear yet (2,12). Different drugs such as sertraline, bupropion, mirtazapine, Modafinil, Dextroamphetamine, Ondansetron, Risperidone, Aripiprazole, Baclofen, Gabapentin and Nalterxon as a treatment of methamphetamine-related disorders were examined, it has been reported that Aripiperazol is the most common drug used (1,12).…”

mentioning

confidence: 99%